Bertram Lum

"Working at Genentech has offered me a rewarding life-time opportunity to work with extremely bright colleagues in a collaborative and cross-functional environment to enable the development of medications for patients which may shape the future of their lives."

15

Years at Genentech

40

Publications

4

Awards & Honors

I joined Genentech in 2003 after a substantial career as a tenured Professor of Clinical Pharmacy and as an academic Clinical Pharmacology/Oncology investigator in a cancer center to contribute to the discovery and development of novel therapies. Genentech has given me the opportunity to work and contribute to the success of a growing pipeline of molecules and learn drug development from an industry perspective in a collaborative, cross functional, team environment. Serving in a number of roles as a scientist, such as lead clinical pharmacologist, Pharmacology Team Leader, Clinical Pharmacology Therapeutic Area Leader, has allowed me to contribute to the global advancement, regulatory filing, and marketing of a number of small molecule and protein therapeutics as well as the development of a number of other investigational medicines.

Featured Publication

Population pharmacokinetics and exposure-response analyses of trastuzumab in patients with advanced gastric or gastroesophageal junction cancer.

Development Sciences’ core mission within gRED (Genentech Research and Early Development) organization is to translate scientific hypotheses into therapeutic possibilities by enabling the discovery and development of safe and effective therapeutics at optimal doses in relevant populations, with the mission of the Clinical Pharmacology component to enable selection of a safe and effective dose, route and regimen for small molecules and biologics by applying the principles of quantitative pharmacology throughout a molecule’s life-cycle is through close collaborations throughout the organization.

My current efforts primarily focus on leading a team on strategic efforts to outline and define strategies for identifying the optimal dose in oncology drug development, which include clinical trial design, analytical techniques for drug concentration – patient response (efficacy, toxicity), the utility of patient reported outcome (quality of life) data, and surveying industry-FDA outcomes of regulatory marketing approvals, such as post-marketing studies and additional clinical pharmacologic (modeling and simulation) analyses. These efforts include engagement of colleagues from within Genentech but also include academia, health authorities, and the American Society of Clinical Pharmacology.
Other areas of focus include working with the Biologics Strategy team to develop strategies and guidance’s for the development of biosimilars, mentoring (scientists, scientist researchers, summer interns, Pharm.D. students), serving as a committee and task-force member for the American Society of Clinical Pharmacology and Therapeutics, and sitting on the editorial board for three oncology focused journals.